| 王树俊,花威,崔广林.双歧杆菌四联活菌片辅助治疗溃疡性结肠炎的疗效及对血清白细胞介素 -17、肿瘤坏死因子 -α水平的影响[J].安徽医药,2021,25(5):1032-1035. |
| 双歧杆菌四联活菌片辅助治疗溃疡性结肠炎的疗效及对血清白细胞介素 -17、肿瘤坏死因子 -α水平的影响 |
| Effect of viable bifidobacterium quadruple combination use in treating parents with ulcer?ative colitis and its influence on serum IL-17,TNF-α expression |
| |
| DOI：10.3969/j.issn.1009-6469.2021.05.047 |
| 中文关键词: 结肠炎，溃疡性 双歧杆菌四联活菌片 白细胞介素 -17 肿瘤坏死因子 -α |
| 英文关键词: Colitis, ulcerative Viable bifidobacterium quadruple Interleukin-17 Tumor necrosis factor -α |
| 基金项目:河南省创新型科技团队项目( C20150009) |
|
| 摘要点击次数: 1335 |
| 全文下载次数: 459 |
| 中文摘要: |
| 目的研究双歧杆菌四联活菌片辅助治疗轻中度溃疡性结肠炎( UC)的疗效及对血清白细胞介素 -17(IL-17)、肿瘤坏死因子 -α(TNF-α)水平的影响。方法选取 2019年 1－10月郑州市第一人民医院及郑州大学第二附属医院收治轻、中度 UC病人 52例，应用随机数字表法分为观察组 26例，采用双歧杆菌四联活菌片联合美沙拉嗪缓释颗粒治疗，对照组 26例，单用美沙拉嗪缓释颗粒治疗。酶联免疫吸附法( ELISA)检测两组治疗前后血清 IL-17、TNF-α水平，比较两组治疗前后疾病活动指数(DAI)评分、内镜评分、临床疗效，并记录不良反应的发生。结果治疗前，两组 DAI评分及内镜评分均差异无统计学意义( P> 0.05)治疗后，观察组 DAI评分由( 6.82±0.54)分降至(2.04±0.12)分，对照组由( 6.90±1.04)分降至(2.74±1.33)分，观察组内镜积分由99±0.78)分降至( 1.69±0.18)分，治疗后观察组及对照组 DAI评分、内镜评分较治疗前均降低，差异有统计学意义( P<(2.0.05)且观察组低于对照组( P<0.05)。治疗前，两组血清 IL-17及 TNF-α水平均差异无统计学意义( P>0.05)治疗后，观察组 IL-17平由( 24.82±3.40)pg/L降至( 7.68±2.11)pg/L，对照组由( 25.00±1.78)pg/L降至( 10.90±1.43)pg/L，观察TNF-α水平由水，组，(51.20±1.03)pg/L降至( 22.49±2.09)pg/L，对照组由( 49.80±2.01)pg/L降至( 31.50±1.65)pg/L，治疗后观察组及对照组 IL-17及 TNF-α水平较治疗前均降低，差异有统计学意义( P<0.05)且观察组低于对照组( P<0.05)。观察组总有效率 92.31%高于对照组 69.23%(P<0.05)。观察组不良反应发生率为 3.85％，低于对照组的 23.08％( P<0.05)。结论双歧杆菌四联活菌片可明显，辅助治疗轻中度 UC，IL-17、TNF-α可能参与了 UC的发生发展。 |
| 英文摘要: |
| Objective To investigate the effect of viable bifidobacterium quadruple combination use in treating parents with mild tomoderate ulcerative colitis(UC) and its influence on serum Interleukin-17(IL-17),Tumor necrosis factor -α (TNF-α) expression.Meth? ods Fifty-two patients with UC were use random number table method divided into trial group(n=26), viable bifidobacterium quadruple combined with mesalazine, and control group(n= 26),only use mesalazine.Disease activity index (DAI), endoscopic score ,clinical efficacy, and adverse reactions were compared between the two groups.Results Before-treatment, there was no significant difference in the DAI and endoscopic score between the two groups(P>0.05), After treatment, DAI decreased from (6.82±0.54) to (2.04±1.12) in thetrial group, and from (6.90±1.04) to (2.74±1.33) in the control group. The endoscopic score decreased from (2.99±0.78) to (1.69±0.81)in the trial group, and from (3.01±1.02) to (2.83±0.99) in the control group.DAI and endoscopic score were reduced in both groups, thedifference was statistically significant(P < 0.05), and the levels in the trial group were shown to be lower than those in the control group (P < 0.05). Before treatment, there was no significant difference in the levels of IL-17,TNF-α between the two groups(P>0.05). After treatment, the levels of IL-17 decreased from (24.82±3.40)pg/L to (7.68±2.11)pg/L in the trial group, and from (25.00±1.78)pg/L to(10.90±1.43)pg/L in the control group. The levels of TNF-α decreased from (51.20±1.03)pg/L to (22.49±2.09)pg/L in the trial group,and from (49.80±2.01)pg/L to (31.50±1.65)pg/L in the control group. The levels of IL-17,TNF-α were reduced in both groups, the difference was statistically significant(P < 0.05), and the levels in the trial group were shown to be lower than those in the control group(P < 0.05). The response rate was significantly higher in the trial group than(92.31%) in the control group (69.23%) ( P<0.05). The rate of drug adverse events in the trial group was 3.85%, which was significantly lower than 23.08%in the control group(P<0.05).Conclusion Viable bifidobacterium quadruple can assist in the treatment of mild to moderate UC, IL-17, TNF-α may be involved in the occurrence and development of UC. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
